BioSpace News Archive

Biotech companies from across the globe are posting strong data at the Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress. Below is a roundup of some of the news coming out of the virtual conference.

Two weeks after announcing concerns about high-levels of carcinogens in popular diabetes drugs, the U.S. Food and Drug Administration announced the first voluntary recalls of this class of drugs manufactured by five companies.

BioSpace takes a look at some of the most recent IPO plans from companies across the globe.

It was a fairly busy week with clinical trial updates and announcements. Here’s a look.

The amount of scientific information unearthed about SARS-CoV-2, the virus that causes COVID-19, in only six months is unprecedented. The speed is remarkable, although much of it will still need to be confirmed over time with more careful study. Still, each day presents new data with a glimmer of hope. Here’s a look at some recent findings.

Although clinical trials are often performed throughout different parts of the world, often their demographic makeup—the gender, age and race of participants—has a certain kind of uniformity.

Decentralized clinical trials gained a foothold in the pharmaceutical industry amidst the COVID-19 pandemic and will continue to be used once the pandemic ends, according to panelists at BIO 2020, speaking Thursday in a virtual session.

The FDA approved Viela Bio’s Uplizna (inebilizumab-cdon) for adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-AQP4 antibody positive. About 80% of all NMOSD patients test positive for anti-AQP4 antibodies.

GlySens Incorporated announced that the company has closed on an incremental $15M financing.

ams announced they have successfully concluded tests using a combination of Senova technology and ams spectral sensor technology to improve performance and usability of a lateral flow-based test to detect antibodies related to the COVID-19 virus.